Wiley-Blackwell, the scientific, technical, medical and scholarly
publishing business of John Wiley & Sons, Inc., and EMBO today announced
that EMBO Molecular Medicine will, as of March 2012, join the Wiley Open
Access publishing program. Articles in the journal will be open access
and free to view, download and share for non-commercial use.
Since its launch in 2009, EMBO Molecular Medicine has attracted
extremely high quality submissions and attained a first Impact Factor of
8.833, placing it 6th in the Medicine Research and Experimental ISI
Category. With its emphasis on translational medicine, the studies
published in EMBO Molecular Medicine are of interest to a wide spectrum
of researchers, clinicians and the public. Converting to open access
allows all readers to benefit from the high-level research advances
reported in EMBO Molecular Medicine, aiding the dissemination of
biomedical research and accelerating discovery.
EMBO Molecular Medicine was the recipient of the 2009 PROSE Award for
Best Journal/ Science, Technology and Medicine.
Dr. Stefanie Dimmeler, Chief Editor of EMBO Molecular Medicine and
Director of the Institute of Cardiovascular Regeneration at the Center
for Molecular Medicine, Goethe University, Frankfurt, noted, “EMBO
Molecular Medicine meets an important need in the scientific community
by reporting the very latest advances in clinical science and basic
research. Open access publishing of articles in EMBO Molecular Medicine
will enhance the visibility of the journal and provide even greater
reach for our published articles.”
Dr. Bernd Pulverer, Head of Scientific Publications at EMBO, said, “EMBO
Molecular Medicine publishes important scientific discoveries with
direct impact on clinical medicine and we are therefore particularly
pleased to be in a position to increase access to this cutting edge
research. EMBO Molecular Medicine is one of the highest profile
biomedical journals to have converted to the Open Access model.”
David Nicholson, Vice President and Journals Publishing Director for
Life Sciences at Wiley-Blackwell, commented: “We are delighted to be
working with our partners at EMBO on the conversion of EMBO Molecular
Medicine to a full open access arrangement. The journal has had a great
impact in the community so far, and we are looking forward to building
on this success as part of our growing activities in open access
publishing.”
The journal is supported by the professional editors Anneke Funk and
Céline Carret and an eminent international panel of Senior Editors, Drs.
Dario Alessi, Giulio Cossu, Uta Francke, Fred Gage, Matthias Hentze,
Edison T. Liu, Philippe Sansonetti and Bart de Strooper.
EMBO Molecular Medicine will publish all future articles under an
Attribution-NonCommercial 3.0 Unported (CC BY-NC 3.0) Creative Commons
License, which permits use, distribution, reproduction and adaptation in
any medium, provided the original work is properly cited and is not used
for commercial purposes. A publication fee will be payable by authors or
their funder on acceptance of their primary research articles.
Please visit EMBO Molecular Medicine's website for further information.
EMBO Molecular Medicine is published by Wiley-Blackwell on behalf of
EMBO.
About Wiley:
Founded in 1807, John Wiley & Sons, Inc. has
been a valued source of information and understanding for more than 200
years, helping people around the world meet their needs and fulfill
their aspirations. Wiley and its acquired companies have published the
works of more than 450 Nobel laureates in all categories: Literature,
Economics, Physiology or Medicine, Physics, Chemistry, and Peace.
Our core businesses publish scientific, technical, medical, and
scholarly (STMS) journals, encyclopedias, books, and online products and
services; professional/trade books, subscription products, training
materials, and online applications and Web sites; and educational
materials for undergraduate and graduate students and lifelong learners.
Wiley's global headquarters are located in Hoboken, New Jersey, with
operations in the U.S., Europe, Asia, Canada, and Australia. The
Company's Web site can be accessed at http://www.wiley.com.
The Company is listed on the New York Stock Exchange under the symbols
JWa and JWb.
Wiley-Blackwell is the international STMS publishing business of John
Wiley & Sons, with strengths in every major academic and professional
field and partnerships with many of the world’s leading societies.
Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+
new books annually in print and online, as well as databases, major
reference works and laboratory protocols. For more information, please
visit http://www.wileyblackwell.com/
or our online platform, Wiley Online Library (wileyonlinelibrary.com),
one of the world’s most extensive multidisciplinary collections of
online resources, covering life, health, social and physical sciences,
and humanities.
About Wiley Open Access:
Wiley Open Access, announced in
February 2011, provides authors wishing to publish their research
outcomes in an open access journal with a range of new high quality
publications which meet the requirements of funding organizations and
institutions where these apply. Wiley Open Access journals are supported
by a network of high-quality journals and societies as well as
internationally-renowned editorial board members.
About EMBO:
EMBO stands for excellence in the life sciences.
The organization enables the best science by supporting talented
researchers, stimulating scientific exchange and advancing policies for
a world-class European research environment.
EMBO is an organization of 1500 leading life scientist members that
fosters new generations of researchers to produce world-class scientific
results. EMBO helps young scientists to advance their research, promote
their international reputations and ensure their mobility. Courses,
workshops, conferences and scientific journals disseminate the latest
research and offer training in cutting-edge techniques to maintain high
standards of excellence in research practice. EMBO helps to shape
science and research policy by seeking input and feedback from our
community and by following closely the trends in science in Europe.
For more information: http://www.embo.org
